Chen Ling, Liu Wei, Wang Meihua, Feng Yang, Xiao Tiechen, Yang Yuxing, Huang Xue
Department of Radiotherapy, Changzhou Cancer Hospital, No.68 Honghe Road, Xinbei District, Changzhou, 213032, Jiangsu, China.
Department of Radiotherapy, Shandong Second Provincial General Hospital, Jinan, 25000, Shandong, China.
Discov Oncol. 2025 Apr 5;16(1):466. doi: 10.1007/s12672-025-02224-9.
Human cervical cancer is the fourth most common malignancies among females worldwide. Radiotherapy is crucial in the treatment of cervical cancer. REV7 is associated with the radiosensitivity of cancer cells. We aimed to investigate the relationship between the REV7 expression and the clinical outcome for patients with cervical cancer who received radiation therapy and identify new markers for studying radiosensitivity in cervical cancer.
The expression of REV7 in 71 cases of cervical squamous cell carcinoma (CSCC) tissues, 20 paracancerous tissues and 20 normal cervical epithelia tissues were analyzed by qRT-PCR and immunohistochemistry (IHC). Among them, 60 patients who underwent intensity-modulated radiation therapy (IMRT) and met the inclusion and exclusion criteria were divided into groups based on the REV7 IHC score: high-expression and low-expression. The relationship between REV7 expression level and short-term efficacy, recurrence and metastasis was investigated. Meanwhile, univariate, multivariate, and Kaplan-Meier analyses were used to analyze the association of REV7 expression with disease-free survival (DFS) and overall survival (OS).
The expression of REV7 is upregulated in CSCC tissues. There was a higher likelihood of progression (pelvic recurrence or distant metastasis) in the group with high REV7 expression (P = 0.024). Moreover, the REV7-high expression patients showed a shorter DFS than the REV7-low expression group (P = 0.011).
The higher expression level of REV7 indicates an unfavorable prognosis in cervical cancer patients undergoing IMRT treatment. REV7 could potentially serve as a novel biomarker and therapeutic target for investigating the radiosensitivity of cervical cancer.
子宫颈癌是全球女性中第四大常见恶性肿瘤。放射治疗在子宫颈癌治疗中至关重要。REV7与癌细胞的放射敏感性相关。我们旨在研究REV7表达与接受放射治疗的子宫颈癌患者临床结局之间的关系，并确定研究子宫颈癌放射敏感性的新标志物。
通过qRT-PCR和免疫组织化学（IHC）分析71例宫颈鳞状细胞癌（CSCC）组织、20例癌旁组织和20例正常宫颈上皮组织中REV7的表达。其中，60例行调强放射治疗（IMRT）且符合纳入和排除标准的患者根据REV7 IHC评分分为高表达组和低表达组。研究REV7表达水平与短期疗效、复发和转移之间的关系。同时，采用单因素、多因素和Kaplan-Meier分析来分析REV7表达与无病生存期（DFS）和总生存期（OS）的相关性。
CSCC组织中REV7表达上调。REV7高表达组发生进展（盆腔复发或远处转移）的可能性更高（P = 0.024）。此外，REV7高表达患者的DFS短于REV7低表达组（P = 0.011）。
REV7较高的表达水平表明接受IMRT治疗的子宫颈癌患者预后不良。REV7可能作为研究子宫颈癌放射敏感性的新型生物标志物和治疗靶点。
